The Effect of Desloratadine on Quality of Life and Nasal Symptoms in Subjects with Perennial Allergic Rhinitis and Asthma

Carvalho, Aurora; Brito, Ulisses; Cunha, J.; Torres, Simões; Duarte, Paula; Pereira, Diogo A.

doi:10.1016/j.jaci.2008.12.502

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier open-label, practice based clinical trials extended real-world clinical experience with desloratadine for the treatment of AR to such diverse populations as those in Hungary, Israel, Malaysia, the Philippines, Portugal, and Saudi Arabia [29,32,33,35-37]. Subjects with AR treated with desloratadine 5 mg once daily in these trials showed significant improvement in ocular and nasal symptoms, especially congestion, after 2 to 4 weeks of treatment.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region

Adham

2011

World Allergy Organization Journal

View full text Add to dashboard Cite

BackgroundAllergic rhinitis (AR) affects up to 36% of the population in the Middle East Gulf States. The second-generation nonsedating antihistamine desloratadine has demonstrated safety and efficacy in the treatment of AR; however, few studies have evaluated this agent in Arab and Asian populations in the Middle East.MethodsThis open-label study enrolled subjects ≥ 12 years with moderate-to-severe AR; they received desloratadine 5 mg QD for 2 weeks. Endpoints included change in mean individual nasal and ocular symptom scores, total symptom score (TSS), and peak nasal inspiratory flow (PNIF) and percentage improvement in global response to therapy.ResultsThere were 602 subjects from 5 Middle East countries enrolled. After 2 weeks, desloratadine significantly (P < 0.0001) reduced mean scores for individual nasal and total ocular symptom scores and TSS. PNIF measures of nasal congestion were significantly (P < 0.0001) improved after treatment. Most subjects obtained complete (38.1%) or marked (47.2%) relief of AR symptoms. Treatment failure was reported in 2.2% of subjects. No adverse events were reported, and no subjects discontinued treatment.ConclusionMost subjects reported significant symptom relief with desloratadine 5 mg/d for 2 weeks. Desloratadine is effective in the treatment of AR in Arab and Asian subjects in the Middle East Gulf region.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region

Adham

2011

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

The Effect of Desloratadine on Quality of Life and Nasal Symptoms in Subjects with Perennial Allergic Rhinitis and Asthma

Cited by 1 publication

References 0 publications

Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region

Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region

Contact Info

Product

Resources

About